CBLN4

CBLN4 is a secreted glycoprotein of the cerebellin family that functions as a trans-synaptic organizer, bridging presynaptic neurexins and postsynaptic netrin receptors (DCC and neogenin-1) to regulate synapse specificity, maintenance, and plasticity. CBLN4 binds neurexins with low affinity through S4-containing splice variants and selectively engages DCC and neogenin-1 via their membrane-proximal fibronectin domains; N-linked glycosylation at two sites masks an intrinsic GluD2-binding capacity, and heteromerization with other Cbln family members shifts receptor-binding specificity in a subunit composition–dependent manner (PMID:28877468, PMID:29782851, PMID:22220752, PMID:17331201). At entorhinal cortex→dentate gyrus synapses, a presynaptic CBLN4–postsynaptic neogenin-1 trans-synaptic complex is essential for long-term potentiation without affecting basal transmission, while CBLN4 also promotes inhibitory GABAergic synapse formation in hippocampal neurons and contributes to long-term excitatory synapse maintenance as revealed by combinatorial knockout analyses (PMID:35544694, PMID:25534236, PMID:29691328). Outside the nervous system, CBLN4 expression in Sertoli cells is directly regulated by SRY and SOX9 during gonadal development (PMID:19211811).

1. 2007 Medium

   Establishing that CBLN4 is a secreted glycoprotein capable of heteromerizing with other cerebellin family members answered whether CBLN4 acts as a soluble signaling molecule and whether its function could be modulated by co-expression with paralogues.

   Evidence Heterologous cell expression, co-immunoprecipitation, and secretion assays in cultured cells

   PMID:17331201

   Open questions at the time

   • Stoichiometry and assembly mechanism of heteromeric complexes not determined
   • In vivo relevance of heteromerization not tested
   • Receptor binding of heteromers not assessed
2. 2009 High

   Demonstrating direct SRY/SOX9 transcriptional regulation of Cbln4 in Sertoli cells revealed a non-neuronal role and identified the first upstream regulators of Cbln4 expression.

   Evidence Chromatin immunoprecipitation identifying SRY binding site, in vivo Sox9 gain/loss-of-function in transgenic mice

   PMID:19211811

   Open questions at the time

   • Downstream function of Cbln4 in gonadal development remains unknown
   • Whether DCC/neogenin-1 signaling is relevant in Sertoli cells not tested
3. 2011 High

   Quantitative binding measurements showed that CBLN4 interacts with neurexins carrying the S4 splice insert but with much lower affinity than CBLN1/2, and lacks synaptogenic activity in standard assays, distinguishing it functionally from other family members.

   Evidence Surface plasmon resonance with neurexin isoforms, cell-based synaptogenesis assays in cerebellar/hippocampal/cortical neurons

   PMID:21356198 PMID:21410790

   Open questions at the time

   • Why CBLN4 retains weak neurexin binding despite poor synaptogenic activity unclear
   • Alternative postsynaptic receptors not yet identified
4. 2012 High

   Identification of DCC as a selective receptor for CBLN4 (but not CBLN1/2) that competes with netrin, combined with the finding that heteromerization with CBLN1 shifts binding from DCC toward neurexin, established subunit composition–dependent receptor specificity as a key regulatory principle.

   Evidence Candidate receptor screen, competition binding, heteromeric co-IP, Cbln4-null mouse generation

   PMID:22220752

   Open questions at the time

   • Functional consequence of DCC engagement by CBLN4 at synapses not determined
   • In vivo validation of subunit-dependent receptor switching not performed
5. 2014 High

   Domain mapping of the CBLN4–DCC interaction to fibronectin domains FN4-6 and demonstration that CBLN4-null mice show transient axon guidance defects linked CBLN4/DCC binding to an in vivo developmental role, while parallel work showed CBLN4 promotes GABAergic synapse formation and maintenance in hippocampal neurons.

   Evidence Radio-ligand competition binding, extracellular protein microarray, CBLN4-null mouse phenotyping, shRNA knockdown and rescue in cultured hippocampal neurons

   PMID:24400119 PMID:25534236

   Open questions at the time

   • Molecular mechanism by which CBLN4 promotes inhibitory synapse formation not defined
   • Whether DCC and neogenin-1 mediate the GABAergic synaptogenic effect unknown
6. 2016 High

   Cell-type-specific expression profiling revealed that Cbln4 is co-expressed in parvalbumin-positive interneurons with a specific neurexin splice isoform, placing the Cbln4–neurexin pair in a molecularly defined circuit element whose disruption elevates network activity and impairs learning.

   Evidence PV+ cell-specific RNA profiling, conditional neurexin splice-site ablation, electrophysiology, behavioral testing in mice

   PMID:27960072

   Open questions at the time

   • Direct demonstration that Cbln4 is the functional ligand in PV+ interneurons (rather than other Cbln family members) not provided
   • Postsynaptic receptor in this circuit not identified
7. 2017 High

   Crystal structures of the Cbln4 C1q trimer and an EM reconstruction of the Cbln4/Nrxn1β complex resolved why Cbln4 cannot bind GluD2 (structural divergence in loop CD) and how neurexin engages the N-terminal region of Cbln4 via strand β10 of the S4 insert.

   Evidence X-ray crystallography at 2.3 Å, negative-stain EM at ~19 Å, SPR/pull-down validation

   PMID:28877468

   Open questions at the time

   • High-resolution structure of the ternary neurexin–Cbln4–postsynaptic receptor complex not obtained
   • Structural basis for DCC/neogenin-1 binding to Cbln4 not resolved
8. 2018 High

   Mutagenesis of two N-linked glycosylation sites unmasked intrinsic GluD2-binding and enhanced neurexin-binding activities of CBLN4, and glycosylation-deficient CBLN4 fully rescued ataxia in Cbln1-null mice, establishing glycosylation as the principal mechanism that restricts CBLN4's receptor engagement in vivo.

   Evidence Site-directed glycosylation-site mutagenesis, in vitro receptor binding, transgenic rescue of Cbln1-null ataxia

   PMID:29782851

   Open questions at the time

   • Physiological conditions under which glycosylation is dynamically regulated are unknown
   • Whether deglycosylation occurs in vivo at specific synapses not tested
9. 2018 High

   Combinatorial knockout of Cbln1/2/4 demonstrated that the cerebellin family collectively maintains excitatory synapse density long-term and prevents seizures, with CBLN4 contributing to synapse maintenance but not initial formation.

   Evidence Single, double, and triple constitutive KO mice; EM and immunofluorescence synapse quantification; behavioral seizure phenotyping

   PMID:29691328

   Open questions at the time

   • Individual contribution of CBLN4 versus redundancy with CBLN1/2 not fully dissected
   • Molecular mechanism of delayed synapse loss not identified
10. 2022 High

    Conditional deletion experiments established that presynaptic CBLN4 and postsynaptic neogenin-1 form a trans-synaptic signaling axis essential for LTP at entorhinal cortex→dentate gyrus synapses, resolving the long-sought postsynaptic receptor for CBLN4 in this circuit.

    Evidence Conditional KO of Cbln4 (presynaptic) and neogenin-1 (postsynaptic) in mice, in vivo LTP recordings, epistasis analysis

    PMID:35544694

    Open questions at the time

    • Downstream signaling cascade activated by neogenin-1 upon CBLN4 binding not characterized
    • Whether this LTP mechanism generalizes beyond EC→DG synapses unknown
11. 2024 Medium

    Identification of METTL14-mediated m6A methylation as a stabilizer of CBLN4 mRNA linked epitranscriptomic regulation to CBLN4 expression levels and neuroprotective function in an Aβ-toxicity model, while a GRID1 amino-terminal domain variant confirmed that GluD1 physically contacts the Cbln2/4 interaction surface.

    Evidence MeRIP and dual-luciferase reporter assays in SK-N-SH cells; co-IP/mutagenesis of GRID1–Cbln complex

    PMID:37944084 PMID:39235700

    Open questions at the time

    • In vivo relevance of m6A regulation of CBLN4 not demonstrated
    • Whether CBLN4 directly binds GluD1 under native glycosylation conditions not tested
    • Neuroprotective mechanism downstream of CBLN4 not defined

• Key unresolved questions include: (1) the structural basis of the CBLN4–neogenin-1/DCC interaction, (2) the intracellular signaling cascade triggered by this trans-synaptic complex to enable LTP, (3) whether CBLN4 glycosylation is dynamically regulated at specific synapses, and (4) the functional role of CBLN4 in non-neuronal tissues such as the developing gonad.
• No high-resolution structure of CBLN4 bound to neogenin-1 or DCC
• Intracellular signaling downstream of neogenin-1 upon CBLN4 binding uncharacterized
• Dynamic regulation of CBLN4 glycosylation in vivo not studied